How soon after endoscopic retrograde cholangiopancreatography (ERCP) biliary stent placement should outpatient imaging be performed for plastic versus self‑expanding metal stents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of Outpatient Imaging After ERCP Biliary Stent Placement

Direct Answer

For plastic biliary stents placed during ERCP, outpatient imaging or repeat ERCP should be scheduled within 3 months to prevent stent obstruction and potentially life-threatening cholangitis. For self-expanding metal stents (SEMS), the timing depends on whether they are covered or uncovered, with fully covered SEMS typically requiring removal or exchange at 4-12 weeks for benign conditions, while uncovered SEMS in malignant disease may remain patent for up to 12 months. 1

Plastic Stent Management

Standard Timing for Removal/Exchange

  • Plastic biliary stents must be removed or replaced within 3 months of placement to minimize the risk of stent obstruction, which can lead to acute cholangitis, hospitalization, and intensive care admission. 1

  • In a study of 374 patients, 19% had delayed stent removal beyond 3 months, and among these patients, 18% required hospitalization for stent obstruction, with 7% developing cholangitis and 4% requiring intensive care. 1

  • The median time to stent clogging is approximately 3 months, making this the critical window for intervention. 2

High-Risk Scenarios Requiring Earlier Follow-up

  • Patients who had outpatient ERCP, required anesthesia assistance, or have non-English primary language are at 2-4 times higher risk of delayed stent removal and should be scheduled more proactively. 1

  • For choledocholithiasis with temporary plastic stent placement, definitive treatment (repeat ERCP for stone extraction followed by cholecystectomy) should occur well before the 3-month mark to prevent recurrent cholangitis. 2

  • Patients with incomplete stone extraction or severe acute cholangitis who received temporary plastic stents require close follow-up and should not wait the full 3 months before repeat intervention. 3

Self-Expanding Metal Stent (SEMS) Management

Fully Covered SEMS (FCSEMS) in Benign Disease

  • For benign biliary strictures and bile leaks, FCSEMS should be removed after 4 or more weeks, with a median stent time of 62 days for strictures and 92 days for bile leaks. 4

  • Optimal duration for FCSEMS in benign conditions is 4-12 weeks (approximately 1-3 months), balancing adequate treatment time against migration risk. 4, 5

  • FCSEMS can remain in place for up to 132 days (mean) without significant complications, though earlier removal at 4-8 weeks is often sufficient for benign conditions. 5

  • Follow-up imaging or endoscopy should be scheduled at 4-6 weeks to assess stent position and plan removal, as migration occurs in approximately 12-29% of cases. 4

FCSEMS in Malignant Disease

  • For malignant biliary obstruction treated with FCSEMS, follow-up should occur at 1-3 months to assess patency and detect early complications. 6

  • Re-intervention is required in approximately 31% of cases during the first year, necessitated by stent migration or occlusion. 6

Uncovered SEMS in Malignant Disease

  • Uncovered SEMS in malignant biliary obstruction have patency rates up to 12 months, significantly longer than plastic stents (3 months). 3

  • Initial follow-up imaging should occur at 3-6 months for uncovered SEMS in malignant disease, with subsequent surveillance based on clinical symptoms and life expectancy. 3

  • Uncovered SEMS should not be used in benign disease as they cannot be removed, become completely epithelialized by 1 year, and are prone to occlusion. 3

Imaging Modality Selection

  • Clinical assessment with liver function tests should be performed at regular intervals to detect early stent dysfunction before symptomatic obstruction occurs. 4

  • ERCP is both diagnostic and therapeutic, allowing simultaneous assessment of stent patency and intervention if obstruction is present. 4

  • For patients with FCSEMS, cholangiography during stent removal documents resolution of strictures or leaks. 4

Critical Pitfalls to Avoid

  • Never allow plastic stents to remain beyond 3 months without removal or exchange, as this dramatically increases the risk of life-threatening cholangitis requiring hospitalization and intensive care. 1

  • Do not assume patients will return for scheduled follow-up—nearly one-fifth of patients miss their scheduled stent removal, particularly those with language barriers or who had outpatient procedures. 1

  • Recognize that stent clogging can occur earlier than 3 months in some patients, particularly those with choledocholithiasis or bile leaks. 2

  • For FCSEMS, schedule removal at 4-12 weeks rather than leaving them indefinitely, as prolonged placement increases migration risk without additional benefit. 4, 5

  • Ensure clear communication and easy scheduling for follow-up ERCP to prevent preventable adverse events from delayed stent management. 1

Special Considerations for Specific Conditions

Choledocholithiasis with Temporary Stenting

  • When plastic stents are placed for incomplete stone extraction, repeat ERCP should be scheduled within 2-8 weeks to complete stone clearance before the stent clogs. 7

  • Following successful stone clearance, cholecystectomy should be performed within 2-4 weeks to prevent recurrent biliary events. 8, 7

Chronic Pancreatitis with Biliary Strictures

  • For benign biliary strictures from chronic pancreatitis treated with FCSEMS, prolonged stent therapy of 6-12 months is effective for stricture remodeling, requiring multiple exchanges during this period. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guideline Summary for Management of Choledocholithiasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Timing Between ERCP and Laparoscopic Cholecystectomy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the immediate treatment for a patient diagnosed with choledocholithiasis (presence of gallstones in the bile ducts)?
Are the definitions of Choledocholithiasis (presence of gallstones in the common bile duct), Cholangitis (inflammation of the bile duct), Cholecystitis (inflammation of the gallbladder), and Cholelithiasis (gallstones) in relation to symptoms such as acholia (lack of bile in the stool), choluria (bile in the urine), and icterus (jaundice) accurate?
What is the differential diagnosis (Ddx) for a patient with new bloody stools and cholangitis, status post (s/p) stent placement and sphincterotomy?
In a patient with cholecystitis and a stent (endoscopic stent) placement, should the stent be removed first or should a cholecystectomy be performed first?
Can cholangitis occur after gallbladder removal?
What is the safest oral analgesic for an outpatient with heart failure and severe knee pain?
What is the recommended treatment algorithm for restless‑leg syndrome, including evaluation of iron deficiency (serum ferritin) and first‑line pharmacologic options?
My very‑low‑density lipoprotein (VLDL) level is 65 mg/dL; what does this indicate and how should I manage it?
Is a startle response in a 9‑month‑old infant normal?
What are hyperkalemia and angioedema, and how should they be treated in a patient on olmesartan?
What is the appropriate assessment and management plan for a previously healthy college‑aged female who experienced a first‑time generalized tonic‑clonic seizure with a post‑ictal fall, associated nausea, vomiting, light‑headedness, intermittent tremor‑like sensations and occasional grip weakness, denies headache, loss of consciousness, chest pain, dyspnea, fever, or focal neurologic deficits, has a normal physical and neurologic examination, no past medical history, no medications, no substance use, and whose last tetanus booster was more than five years ago?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.